Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: A randomized controlled trial

PLoS Medicine

Volumn 11, Issue 8, 2015, Pages

  Bigira, Victor ^a   Kapisi, James ^a   Clark, Tamara D ^b   Kinara, Stephen ^a   Mwangwa, Florence ^a   Muhindo, Mary K ^a   Osterbauer, Beth ^b   Aweeka, Francesca T ^b   Huang, Liusheng ^b   Achan, Jane ^c   Havlir, Diane V ^b   Rosenthal, Philip J ^b   Kamya, Moses R ^c   Dorsey, Grant ^b  

^a INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARTEMETHER PLUS BENFLUMETOL; ASPARTATE AMINOTRANSFERASE; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; PIPERAQUINE; PROTECTIVE AGENT; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PYRIMETHAMINE; QUINOLINE DERIVATIVE; SULFADOXINE;

ANEMIA; ANTIMALARIAL ACTIVITY; ARTICLE; BLOOD SMEAR; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; FEVER; HUMAN; INFANT; MALARIA; MALE; OPEN STUDY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; THROMBOCYTOPENIA; COHORT ANALYSIS; DRUG COMBINATION; INCIDENCE; PARASITOLOGY; UGANDA;

ANTIMALARIALS; ARTEMISININS; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; HUMANS; INCIDENCE; INFANT; MALARIA; MALE; PYRIMETHAMINE; QUINOLINES; SULFADOXINE; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; UGANDA;

EID: 84936149907     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001689     Document Type: Article

References (35)

1. World Health Organization (2012) World malaria report 2012. Available: http://www.who.int/malaria/publications/world_malaria_report_2012/en/. Accessed 8 October 2013.
2. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, et al. (2009) Efficacy and safety of intermittent preventive treatment with sulfadoxinepyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374: 1533-1542.
3. Sandison TG, Homsy J, Arinaitwe E, Wanzira H, Kakuru A, et al. (2011) Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ 342: d1617.
4. Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, et al. (2005) Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 192: 1823-1829.
5. Wilson AL (2011) A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS ONE 6: e16976.
6. White NJ (2005) Intermittent presumptive treatment for malaria. PLoS Med 2: e3.
7. Okello PE, Van Bortel W, Byaruhanga AM, Correwyn A, Roelants P, et al. (2006) Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 75: 219-225.
8. World Health Organization (2010) Guidelines for the treatment of malaria-second edition. http://www.who.int/malaria/publications/atoz/9789241547925/en/. Accessed 8 October 2013.
9. Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, et al. (2013) Pharmacokinetic predictors for recurrent malaria after dihydroartemisininpiperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis 207: 1646-1654.
10. Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, et al. (2012) Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 91: 497-505.
11. Geerligs PD, Brabin BJ, Eggelte TA (2003) Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bull World Health Organ 81: 205-216.
12. Gosling RD, Cairns ME, Chico RM, Chandramohan D (2010) Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther 8: 589-606.
13. World Health Organization (2007) Technical Expert Group meeting on intermittent preventive treatment in pregnancy (IPTp). Available: http://www.who.int/malaria/publications/atoz/9789241596640/en/. Accessed 8 October 2013.
14. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, et al. (2009) Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 374: 1521-1532.
15. World Health Organization (2010) WHO policy recommendation on intermittent preventive treatment during infancy with sulphadoxine-pyrimethamine (SPIPTi) for Plasmodium falciparum malaria control in Africa. Available: http://www.who.int/malaria/news/WHO_policy_recommendation_IPTi_032010.pdf. Accessed 2 July 2014.
16. Naidoo I, Roper C (2011) Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. Parasitology 138: 1469-1479.
17. Odhiambo FO, Hamel MJ, Williamson J, Lindblade K, ter Kuile FO, et al. (2010) Intermittent preventive treatment in infants for the prevention of malaria in rural western Kenya: a randomized, double-blind placebo-controlled trial. PLoS ONE 5: e10016.
18. Senn N, Rarau P, Stanisic DI, Robinson L, Barnadas C, et al. (2012) Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial. PLoS Med 9: e1001195.
19. World Health Organization (2012) WHO policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. Available: http://www.who.int/malaria/publications/atoz/who_smc_policy_recommendation/en/index.html. Accessed 8 October 2013.
20. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE (2011) Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis 53: 224-230.
21. Mytton OT, Ashley EA, Peto L, Price RN, La Y, et al. (2007) Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg 77: 447-450.
22. Four Artemisinin-Based Combinations (4ABC) Study Group (2011) A head-tohead comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 8: e1001119.
23. Cisse B, Cairns M, Faye E, NDiaye O, Faye B, et al. (2009) Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS ONE 4: e7164.
24. Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, et al. (2012) Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 56: 1571-1577.
25. Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, et al. (2007) Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med 4: e242.
26. Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, et al. (1997) Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 350: 844-850.
27. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, et al. (2005) Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365: 1481-1483.
28. Guinovart C, Dobano C, Bassat Q, Nhabomba A, Quinto L, et al. (2012) The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial. PLoS ONE 7: e32362.
29. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, et al. (2010) In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother 54: 1200-1206.
30. Some AF, Sere YY, Dokomajilar C, Zongo I, Rouamba N, et al. (2010) Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 54: 1949-1954.
31. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF (2005) Piperaquine: a resurgent antimalarial drug. Drugs 65: 75-87.
32. Uganda Bureau of Statistics, ICF Macro (2010) Uganda Malaria Indicator Survey 2009. Calverton (Maryland): ICF Macro. Available: http://www.measuredhs.com/pubs/pdf/MIS6/MIS6.pdf. Accessed 8 October 2013.
33. Malaria Atlas Project (2010) The spatial distribution of Plasmodium falciparum malaria stratified by endemicity class map in 2010 in Uganda. Available: http://www.map.ox.ac.uk/browse-resources/endemicity/Pf_class/UGA/. Accessed 24 January 2014.
34. Yeka A, Gasasira A, Mpimbaza A, Achan J, Nankabirwa J, et al. (2011) Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop 121: 184-195.
35. Conrad M, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, et al. (2014) Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis. E-pub ahead of print. doi:10.1093/infdis/jiu141